IP Library Granted Patent US 9,474,760
Granted Patent B2
US 9,474,760 · App. 14/535,759 · Granted Oct 25, 2016

Hypotensive lipid and timolol compositions and methods of using same

Inventors: June Chen (San Juan Capistrano, CA); David F. Woodward (Lake Forest, CA); Alexander B. Kharlamb (Irvine, CA)
Assignee: ALLERGAN, INC.
A61K31/5377A61K9/0048A61K31/165A61K31/535A61K31/557A61K31/5575A61K45/06A61K47/186A61K47/10Y10S514/913
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,474,760
App. No.
14/535,759
Granted
Oct 25, 2016
Kind
B2
Abstract

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

Claims (4)

1. An aqueous composition suitable for ocular administration, the composition comprising 0.68% (w/v) timolol maleate, 0.03% (w/v) bimatoprost, and benzalkonium chloride in a single composition, wherein the composition is effective in reducing intraocular pressure when applied to an eye.

2. The composition of claim 1 , wherein administration of the composition reduces one or more side effects as compared to the administration of another composition comprising 0.03% (w/v) bimatoprost without timolol maleate.

3. The composition of claim 2 , wherein the reduced side effect is conjunctival hyperemia.

4. The composition of claim 1 , wherein the composition further comprises a citrate buffer, a phosphate buffer, and has a pH of about 7.3.

Continuity (5)
Continuation 14062691 · Oct 24, 2013
Continuation 12408125 · Mar 20, 2009
Continuation 10153043 · May 22, 2002
Provisional Application 60294845 · May 31, 2001
Related Publication 20150150880A1 · Jun 4, 2015